

File No.- BMSIC/40030/771-2025/9315

दिनांक:-28/11/2025

बिहार चिकित्सा सेवाएं एवं आधारभूत संरचना निगम लि०, बिहार पटना
BMSICL की निविदा संख्या- BMSIC/DRUGS/25-11 से संबंधित प्राप्त ई-निविदाओं के तकनीकी
मूल्यांकन विवरणी पर साक्ष्य सहित दावा/आपत्ति की माँग संबंधी सूचना

बिहार चिकित्सा सेवाएं एवं आधारभूत संरचना निगम लि०, द्वारा औषधियों की अधिप्राप्ति हेतु ई-निविदा (निविदा संख्या- **BMSIC/DRUGS/25-11**) आमंत्रित की गई थी, जिसके आलोक में निर्धारित समय सीमा के अन्तर्गत कुल 47 (सैंतालीस) ई-निविदा प्राप्त हुई। उक्त 47 (सैंतालीस) ई-निविदा के दस्तावेजों के प्राथमिक तकनीकी मूल्यांकन के उपरान्त तैयार की गई तकनीकी मूल्यांकन विवरणी के दावा/आपत्ति के आमंत्रण हेतु BMSICL के **website (www.bmsicl.gov.in)** एवं e-proc 2.0 के **website (www.eproc2.bihar.gov.in)** पर अपलोड की गई है।

निविदा में भाग लेने वाले निर्माता संस्थान अथवा अन्य आपूर्तिकर्ता अपलोड किये गए उपर्युक्त तकनीकी मूल्यांकन प्रपत्र में किसी प्रकार की विसंगति पाये जाने की स्थिति में, साक्ष्य सहित अपना दावा/आपत्ति दिनांक 05/12/2025 के अपराह्न 05:00 बजे तक केवल e-proc 2.0 के **website (www.eproc2.bihar.gov.in)** के माध्यम से कर सकते हैं।

e-proc 2.0 के **website (www.eproc2.bihar.gov.in)** के अलावा अन्य किसी माध्यम से प्राप्त किसी प्रकार के दावा/आपत्ति पर कोई विचार नहीं किया जायेगा।

अनुलग्नक- यथोक्त


महाप्रबंधक (अधिप्राप्ति)

ज्ञापांक:- BMSIC/40030/771-2025/9315

दिनांक:-28/11/2025

प्रतिलिपि :- सहायक प्रबंधक (सिस्टम) एवं प्रबंधक (औषधि) को सूचनार्थ प्रेषित। निदेश है कि सूचना का अनुलग्नक सहित अविलंब BMSICL के **website (www.bmsicl.gov.in)** एवं e-proc2 (**www.eproc2.bihar.gov.in**) पर अपलोड करना सुनिश्चित करें।


महाप्रबंधक (अधिप्राप्ति)



TENDER NO. BMSIC/DRUGS/25-11

Check list - I: Evaluation sheet to be used for preliminary evaluation of technical bids

Company Name : - Pushkar Pharma. Total Number of Pages Submitted in bid documents: - 1 to 126

Sl. No	SBD clause serial No	Description of the Clause/ Technical Eligibility Criteria as per SBD as mentioned in the Check List	Document/ fees submission status (Yes/ No)	Page number	Do the provided documents meet the eligibility criteria ? (Yes/ No)	Remarks
1	3. (a)	Tender Fee (Non-Refundable) of Rs 10,000/- + GST @18%, Total Rs 11,800 shall be submitted online (On E-Proc-2). This fee is payable only once for one tender irrespective of items contained therein	Yes	30	Yes	
2	3.(b)	b)EMD shall be submitted ONLY in form of Bank Guarantee (Offline mode), drawn in favor of Managing Director, Bihar Medical Services and Infrastructure Corporation Limited from any Scheduled/Nationalized bank payable at Patna, as mentioned in Clause 2,as per following table:- S.N.No. of drugs quotedEMD Amount 1Upto 5 drugsRs1,00,000/- (One Lakh only) 2For 6 to 10 DrugsRs 2,00,000/- (Two Lakh only) 3For 11 to 15 DrugsRs 3,00,000/- (Three Lakh only) 4For 16 to 20 DrugsRs 4,00,000/- (Four Lakh only) 5More than 20 Drugs Rs 5,00,000/- (Five Lakh only)	Yes	35-39	Yes	
3	3.(c)	Documentary evidence of the constitution of the company/firm/Proprietorship such as Memorandum and Articles of Association, Partnership Deed etc. should be submitted with details of the Name, Address, Telephone Number, Fax Number, e-mail address of the firm and of the Managing Director / Partners / Proprietor should be submitted.	Yes	10-17	Yes	
4	3.(l)	Copies of the Audited Balance Sheet and Profit and Loss statement showing details of their annual average turnover not less than 25 Crores (Twenty-Five) for any three of the last four consecutive financial years (Auditor/CA certificate of turnover will not be accepted). Self-attested copies are to be submitted. It's mandatory for the firm to provide a document for the Unique Document Identification Number (UDIN) to verify the documents.	Yes	44-53	No	Kindly Submit 3CD Statement for verifying Turnover Amount mentioned at UDIN Report for F.Y-2021-2022 & F.Y-2022-2023 & F.Y-2023-2024.
5	3.(m)	Copy of Income Tax Return for any three of last four Consecutive Assessment years should be submitted (self-attested).	Yes	31-33	Yes	
6	3.(p)	Copy of PAN Card of the bidder company should be submitted (self-attested).	Yes	34	Yes	
7	3.(q)	Copy of certificate of valid GST registration of the bidder company should be submitted (self-attested).	Yes	07-09	Yes	

Anhar Singh

S. S. S. S.

TENDER NO. BMSIC/DRUGS/25-11

Check list - II: Evaluation sheet to be used for preliminary evaluation of technical bids

Company Name:- M/s Pushkar Pharma. Total Number of Pages Submitted in bid documents:- 126

Sl. No	SBD Clause serial No	Description of the Clause/ Technical Eligibility Criteria as per SBD, as mentioned in Check List	Document/ fees submission status (Yes/ No)	Page Number as numbered by BMSICL	Do the provided documents meet the eligibility criteria ? (Yes/ No)	Remarks
1	3.(d)	The details of Bidder Name, Address, Telephone Number, Fax. Number, e-mail address of the bidder and of the Managing Director / Partners / Proprietor should be submitted in Annexure-V.	Yes	125	Yes	
2	3.(e)	Power of Attorney or Resolution of the Board by which the authorized signatory has been authorized by the bidder firm to sign the documents should be submitted.	Yes	5-6	Yes	
3	3.(f)	Minimum three years old valid Manufacturing License of the quoted product.	Yes	80-103	No	(i) Dosage form of NIT sr. no. 34 is not as per NIT i.e. Depot Injection. (ii) Pack size of quoted product NIT sr. no. 35 & 47 is not as per NIT. (iii) Product specification of quoted product NIT sr. no. 52 is not as per NIT.
4		Manufacturing License along with approved product list must be valid till the last date of the submission of tender.	Yes	80-103	No	
5		•Market standing certificate & Manufacturing certificate issued by the Licensing Authority as a Manufacturer for each drug quoted for the last 3 years. The Market Standing Certificate must have been issued within preceding one year from the last date of submission of tender (Certificate should be enclosed with list of items) except for the drugs falling under the category of 'New Drug' as defined by CDSCO (Central Drugs Standard Control Organisation). If permission in Form 46 from DCGI has been obtained, then the 3 years Manufacturing & Market standing clause will be relaxed. The provisions of Rule 122 E of Drugs and Cosmetics Act rule 1945 shall be applicable. Explanation- In case of Importers Permission in Form 45 from DCGI is required as Per Drugs & Cosmetics Act 1940 & Rules 1945. For drugs with a patent that expired less than 2 years ago from the last date of bid submission: Non-patent holding bidders should submit a valid Market Standing Certificate and valid drug license, issued by the State Drug Licensing Authority in support of the claim. Bidders will be eligible only if one batch of new drug has been successfully manufactured/ imported for commercial use at the time of bidding. Bidders should submit document regarding patent expired less than 2 years ago from the last date of bid submission.	Yes	54-79	No	(i) Submitted MSC dosage form of NIT sr. no. 34 is not as per NIT. (ii) Submitted MSC specification of NIT sr .no. 52 is not as per NIT.
6		For all regulated products, the bidder should have at least two years of manufacturing and marketing experience of the particular items as a manufacturer for each regulated product quoted in the tender. However, this would not apply to regulated products which have been licensed by DCGI less than two years ago. A certificate from DCG (I) shall be required for all new regulated products to this effect.	NA	NA	NA	

Jash
25-11-25HWP
14/11/25Dushy
17/11/25SKA
13/11/25

7		FFS (Flow Fill & Seal Process) Technology will be accepted wherever applicable.	NA	NA	NA	
8		Valid Pollution Control Clearance Certificate in accordance with Water [Prevention and control of Pollution] Act, 1974 & Air [Prevention and control of Pollution] Act, 1981 and Hazardous Wastes (Management, Handling & Trans Boundary Movement) Rules 2008 (Self Attested Copy of Certificate to be enclosed) (as applicable).	Yes	104-119	Yes	Challan & Application for renewal submitted.
9		Bidders shall submit self-attested copies of required manufacturing license and approved product list in support of above-mentioned condition and they are required to specify the quoted product in their approved product list by highlighting it.	Yes	80-103	No	(i) Dosage form of NIT sr. no. 34 is not as per NIT i.e. Depot Injection. (ii) Pack size of quoted product NIT sr. no. 35 & 47 is not as per NIT. (iii) Product specification of quoted product NIT sr. no. 52 is not as per NIT.
10	3.(g)	In case of Importer, the bidder (importer) firm must have minimum three yearsold valid import License of the quoted product. All Quoted products should be accompanied by their invoices, statement and import License showing that the quoted product is being imported and sold in India by the bidder (Importer) firm minimum for Last three years. Import license must be valid on the last date of submission of tender.	NA	NA	NA	
11	3.(h)	Bidder must have Market Standing Certificate (in India) of minimum three years issued by the concerned Licensing Authority from Drugs Control Department for the quoted product. The Market Standing Certificate must have been issued within preceding one year from the last date of submission of tender. Self-attested copies are to be submitted.	Yes	54-79	No	(i) Submitted MSC dosage form of NIT sr. no. 34 is not as per NIT. (ii) Submitted MSC specification of NIT sr .no. 52 is not as per NIT.
12	3.(i)	Non-Conviction Certificate (NCC) issued by the concerned Licensing Authority from Drugs Control Administration of the state for last three years should be submitted (wherever applicable). It should be not more than one year old. Self-attested copies are to be submitted.	Yes	20-24	Yes	
13	3.(j)	WHO-GMP/GMP (Good Manufacturing Practice) as per revised Schedule- 'M'/COPP Certificate of the manufacturing unit issued by the Licensing Authority/Drugs Control Department, (wherever applicable). The GMP certificate must not be older than one year from the date of publication of tender. Self-attested copies are to be submitted. Explanation- Generally the GMP Certificate is issued for one-year validity. Hence the provision that it should not be older than one year from the date of publication of tender implies mutatis mutandis that the GMP certificate should remain valid till the date of submission of tender.	Yes	18	Yes	
14	3.(k)	Maximum Production Capacity Certificate (Section wise) issued by concerned Licensing Authority from Drugs Control Department highlighting the quoted product section (wherever applicable). Self-attested copies are to be submitted. In case of Importer, an affidavit (with Stamp) sworn before first class magistrate/ Notary stating the batch production capacity of the firm and also that said production (Importing) capacity shall be adequate for requirement laid in NIT. Importer will have also to submit Invoices/evidence of import in items of said product with quantity details.	Yes	29	Yes	

SKR
23/11/25

Sub
23-11-25

14/11/25

18/11/25

15	3.(n)	The tenderer should give an affidavit (with stamp) sworn before first class magistrate / Notary stating that the firm & its quoted product is not black listed /Debarred currently (as on the date of submission of the tender) by Central Government / Central Government agencies/any state government or any of the state government agencies / or any Drug procurement agencies or by BMSICL asper Annexure-II.	Yes	3-4	Yes	
16	3. (o)	List of items quoted in prescribed format as per Annexure-III duly signed.	Yes	1-2	Yes	
17	5.(k)	An Affidavit (with stamp) regarding acceptance of tender conditions to be submitted by the bidding firm as per Annexure-IV .	Yes	43	Yes	
18	5.(l)	Filled check list as per given Annexure-VI to be submitted at the time of uploading the bid.	Yes	123-124	Yes	
19	7.(c)	Power of Attorney or Resolution of the Board by which the authorized signatory has been authorized by the bidder firm should sign the documents in cases where person other than the Managing Director/Managing Partner or sole Proprietor signs the document.	Yes	5-6	Yes	
20	10.(c)	If a particular document/Certificate to be uploaded as specified in bid, is not applicable for a bidder, the bidder shall attach a scanned copy of declaration in the letter head stating that the specific document is not applicable/exempted for the bidder in connection to this tender.	NA	NA	NA	
21	2(d) Explanation	Explanation- In order to ensure procurement of the tendered drugs at the most appropriate and competitive rate, the bidders are directed to quote their lowest price as compared to the Rate provided to their respective Distributors/ Dealers/Wholesalers/ Carrying and Forwarding Agents/Authorized depot sales point in the State of Bihar. A Notarized affidavit to this effect on a Rs 100/- Non-judicial Stamp Paper should be submitted with the Bid in the prescribed format as mentioned in Annexure-VIII	Yes	120	Yes	

SKS
13/11/25

2025
05.11.25

14/11/25

15/11/25

TENDER NO. BMSIC/DRUGS/25-11

Check list - III: Evaluation sheet to be used for preliminary evaluation of technical bids

Company Name: M/s Pushkar Pharma. Total Number of Pages Submitted in bid documents: 126

Sheet to be used for verification of product approval and market standing

Sl. No	NIT Sl. No	Name of the Quoted Drug		Pharmacopocial Specification/ Strength		Dosage Form		Pack Size		Approval Details			Last 3yrs market standing certificate/ New Drug
		As per NIT	As per Approval	As per NIT	As per Approval	As per NIT	As per Approval	As per NIT	As per Approval	Approval From	Approved Upto	Approved in Brand /Generic Name	
1	3	Acyclovir	Acyclovir	500 mg	500 mg	Powder for Injection	Injection	Vial	Vial	26.04.2021 (page no. 85)	08.01.2029 (page no. 80)	Generic	Submitted (page no. 55)
2	4	Adrenaline	Adrenaline	1 mg/ml	1 mg/ml	Injection	Injection	1ml Ampoule	1 ml	19.07.2013 (page no. 86)	08.01.2029 (page no. 80)	Generic	Submitted (page no. 74)
3	11	Bupivacaine	Bupivacaine	0.50%	0.50%	Injection	Injection	20ml Vial	20 ml	11.06.2010 (page no. 87)	08.01.2029 (page no. 80)	Generic	Submitted (page no. 68)
4	12	Cefotaxime	Cefotaxime	500 mg	500 mg	Powder for Injection	Injection	Vial	Vial	09.01.2009 (page no. 88)	08.01.2029 (page no. 80)	Generic	Submitted (page no. 59)
5	18	Diazepam	Diazepam	5 mg/ml	5 mg/ml	Injection	Injection	2ml Ampoule	2 ml	09.01.2009 (page no. 89)	08.01.2029 (page no. 80)	Generic	Submitted (page no. 75)
6	19	Dicyclomine HCL	Dicyclomine HCL	10 mg/ml	10 mg/ml	Injection	Injection	2 ml Ampoule	2 ml	08.12.2011 (page no. 90)	08.01.2029 (page no. 80)	Generic	Submitted (page no. 61)

SR
23/11/25

25-11-25

14/11/25

18/11/25

7	34	Fluphenazine	Fluphenazine	25 mg/ml	25 mg/ml	Depot Injection	Injection (Not as per NIT)	5ml vial	5 ml	29.01.2021 (page no. 91)	08.01.2029 (page no. 80)	Generic	Dosage form of submitted MSC is not as per NIT. (page no. 57)
8	35	Furosemide	Furosemide	10 mg/ ml	10 mg/ ml	Injection	Injection	2 ml Amp	5, 10, 15, 20, 30, 50 ml (Not as per NIT)	17.05.2016 (page no. 92)	08.01.2029 (page no. 80)	Generic	Submitted (page no. 75)
9	40	Haloperidol	Haloperidol	5 mg/ml	5 mg/ml	Injection	Injection	1ml Ampoule	1 ml	29.01.2021 (page no. 93)	08.01.2029 (page no. 80)	Generic	Submitted (page no. 63)
10	47	Latanoprost	Latanoprost	0.005%	50 mcg	Drops	Drops	2.5ml	3 ml, 5 ml, 10 ml, 15 ml (Not as per NIT)	13.09.2016 (page no. 95)	08.01.2029 (page no. 80)	Generic	Submitted (page no. 55)
11	48	Levetiracetam	Levetiracetam	100 mg/ml	100 mg/ml	Injection	Injection	5 ml Vial	5 ml	06.07.2016 (page no. 94)	08.01.2029 (page no. 80)	Generic	Submitted (page no. 55)
12	52	Lignocaine (A) + Adrenaline (B)	Lignocaine (A) + Adrenaline (B)	2% (A) + 1:200000 (5 mcg/ml) (B)	Each ml contains: Lignocaine Hydrochloride IP 21.3 mg Adrenaline (As Bitartrate) IP 0.005 mg (Specification is not as per NIT)	Injection	Injection	30ml Vial	30 ml	09.01.2009 (page no. 96)	08.01.2029 (page no. 80)	Generic	Submitted MSC specification is not as per NIT. (page no. 70)
13	55	Methylprednisolone	Methylprednisolone	40 mg/ml	40 mg/ml	Injection	Injection	Vial	1 ml, 2 ml, 3 ml, 5 ml, 10 ml, 20 ml, 30 ml	07.08.2010 (page no. 97)	08.01.2029 (page no. 80)	Generic	Submitted (page no. 55)
14	56	Methylprednisolone	Methylprednisolone	500 mg	500 mg	Injection	Injection	Vial	Vial	19.07.2013 (page no. 98)	08.01.2029 (page no. 80)	Generic	Submitted (page no. 72)

SKS
13/11/25

14/11/25

17/11/25

15	57	Methylprednisolone	Methylprednisolone	1000 mg	1000 mg	Injection	Injection	Vial	Vial	19.07.2013 (page no. 98)	08.01.2029 (page no. 80)	Generic	Submitted (page no. 65)
16	61	Natamycin	Natamycin	5%	5%	Drops	Drops	5ml	5 ml	09.01.2009 (page no. 99)	08.01.2029 (page no. 80)	Generic	Submitted (page no. 55)
17	64	Pentazocin	Pentazocin	30 mg/ml	30 mg/ml	Injection	Injection	1ml Ampoule	1 ml	16.07.2012 (page no. 100)	08.01.2029 (page no. 80)	Generic	Submitted (page no. 76)
18	65	Pheniramine	Pheniramine	22.75 mg/ml	22.75 mg/ml	Injection	Injection	2 ml Ampoule	2 ml	09.01.2009 (page no. 101)	08.01.2029 (page no. 80)	Generic	Submitted (page no. 69)
19	67	Proparacaine	Proparacaine	0.50%	0.50%	Drops	Drops	5ml	5 ml	24.08.2009 (page no. 102)	08.01.2029 (page no. 80)	Generic	Submitted (page no. 67)
20	84	Xylometazoline	Xylometazoline	0.10%	0.10%	Nasal drops	Nasal drops	10 ml Bottle	10 ml	29.06.2011 (page no. 103)	08.01.2029 (page no. 80)	Generic	Submitted (page no. 79)

SKR
13/11/25

SKR
23.11.25

SKR
14/11/25

SKR
12/11/25

TENDER NO. BMSIC/DRUGS/25-11

Check list - IV: Evaluation sheet to be used for preliminary evaluation of technical bids






Company Name:- M/s Pushkar Pharma. Total Number of Pages Submitted in bid documents:- 126

Sheet for verification of licence details

Sl. No.	NIT Sl. No	Name of the Drug as per NIT	Manufacturer		Importer		Validity		GMP/ WHO GMP/ COPP (Import)	
			Forms Number	Manufacturing license Number	Forms Number	Import license Number	From	To	From	To
1	3	Acyclovir	25 & 28	S-MNB/08/28 & S-MB/08/29	NA	NA	09.01.2009 (page no. 82, 84)	08.01.2029 (page no. 80)	04.09.2025	03.12.2025 (page no. 18)
2	4	Adrenaline	25 & 28	S-MNB/08/28 & S-MB/08/29	NA	NA	09.01.2009 (page no. 82, 84)	08.01.2029 (page no. 80)	04.09.2025	03.12.2025 (page no. 18)
3	11	Bupivacaine	25 & 28	S-MNB/08/28 & S-MB/08/29	NA	NA	09.01.2009 (page no. 82, 84)	08.01.2029 (page no. 80)	04.09.2025	03.12.2025 (page no. 18)
4	12	Cefotaxime	25 & 28	S-MNB/08/28 & S-MB/08/29	NA	NA	09.01.2009 (page no. 82, 84)	08.01.2029 (page no. 80)	04.09.2025	03.12.2025 (page no. 18)
5	18	Diazepam	25 & 28	S-MNB/08/28 & S-MB/08/29	NA	NA	09.01.2009 (page no. 82, 84)	08.01.2029 (page no. 80)	04.09.2025	03.12.2025 (page no. 18)

S/R
13/11/25Sd/-
25-11-25Sd/-
14/11/25Sd/-
17/11/25

6	19	Dicyclomine HCL	25 & 28	S-MNB/08/28 & S-MB/08/29	NA	NA	09.01.2009 (page no. 82, 84)	08.01.2029 (page no. 80)	04.09.2025	03.12.2025 (page no. 18)
7	34	Fluphenazine	25 & 28	S-MNB/08/28 & S-MB/08/29	NA	NA	09.01.2009 (page no. 82, 84)	08.01.2029 (page no. 80)	04.09.2025	03.12.2025 (page no. 18)
8	35	Furosemide	25 & 28	S-MNB/08/28 & S-MB/08/29	NA	NA	09.01.2009 (page no. 82, 84)	08.01.2029 (page no. 80)	04.09.2025	03.12.2025 (page no. 18)
9	40	Haloperidol	25 & 28	S-MNB/08/28 & S-MB/08/29	NA	NA	09.01.2009 (page no. 82, 84)	08.01.2029 (page no. 80)	04.09.2025	03.12.2025 (page no. 18)
10	47	Latanoprost	25 & 28	S-MNB/08/28 & S-MB/08/29	NA	NA	09.01.2009 (page no. 82, 84)	08.01.2029 (page no. 80)	04.09.2025	03.12.2025 (page no. 18)
11	48	Levetiracetam	25 & 28	S-MNB/08/28 & S-MB/08/29	NA	NA	09.01.2009 (page no. 82, 84)	08.01.2029 (page no. 80)	04.09.2025	03.12.2025 (page no. 18)
12	52	Lignocaine (A) + Adrenaline (B)	25 & 28	S-MNB/08/28 & S-MB/08/29	NA	NA	09.01.2009 (page no. 82, 84)	08.01.2029 (page no. 80)	04.09.2025	03.12.2025 (page no. 18)
13	55	Methylprednisolone	25 & 28	S-MNB/08/28 & S-MB/08/29	NA	NA	09.01.2009 (page no. 82, 84)	08.01.2029 (page no. 80)	04.09.2025	03.12.2025 (page no. 18)

 13/11/25
 25-11-25
 14/11/25

 18/11/25

14	56	Methylprednisolone	25 & 28	S-MNB/08/28 & S-MB/08/29	NA	NA	09.01.2009 (page no. 82, 84)	08.01.2029 (page no. 80)	04.09.2025	03.12.2025 (page no. 18)
15	57	Methylprednisolone	25 & 28	S-MNB/08/28 & S-MB/08/29	NA	NA	09.01.2009 (page no. 82, 84)	08.01.2029 (page no. 80)	04.09.2025	03.12.2025 (page no. 18)
16	61	Natamycin	25 & 28	S-MNB/08/28 & S-MB/08/29	NA	NA	09.01.2009 (page no. 82, 84)	08.01.2029 (page no. 80)	04.09.2025	03.12.2025 (page no. 18)
17	64	Pentazocin	25 & 28	S-MNB/08/28 & S-MB/08/29	NA	NA	09.01.2009 (page no. 82, 84)	08.01.2029 (page no. 80)	04.09.2025	03.12.2025 (page no. 18)
18	65	Pheniramine	25 & 28	S-MNB/08/28 & S-MB/08/29	NA	NA	09.01.2009 (page no. 82, 84)	08.01.2029 (page no. 80)	04.09.2025	03.12.2025 (page no. 18)
19	67	Proparacaine	25 & 28	S-MNB/08/28 & S-MB/08/29	NA	NA	09.01.2009 (page no. 82, 84)	08.01.2029 (page no. 80)	04.09.2025	03.12.2025 (page no. 18)
20	84	Xylometazoline	25 & 28	S-MNB/08/28 & S-MB/08/29	NA	NA	09.01.2009 (page no. 82, 84)	08.01.2029 (page no. 80)	04.09.2025	03.12.2025 (page no. 18)

Note:- Assisted in technical evaluation in reference to letter no. BMSIC/40030/771-2025/8591 dt 07.11.2025 on the basis of documents provided by BMSICL as check list II, III & IV. Provided checklist compiled with due diligence and care. In spite, some inadvertent discrepancies could have been crept in. Humble request to all concerned to bring to the notice in due time if any discrepancies are observed for rectification.

SK
13/11/25

804
25-11-25

14/11/25

18/11/25